TuHURA Biosciences, Inc./NV

HURA

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001498382


None

No letter

2 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $27.4M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	short runway, thin data, degenerate in... not computable: dilution, distress
Inputs computable	2 of 14
Graded from	filings received through Apr 30, 2026 196 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	$1.51 2026-11-11; market equity $96.2M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 31, 2026

We are a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to "trick" the body's immune system to attack tumor cells by making tumor cells look like bacteria. Our lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 40.8						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

required facts have no common fiscal period end						
Accruals ratio	(10.2%)	(6.6%)		40.8	801	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 91.6						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	not computable	(0.35)				
required facts have no common fiscal period end						
Net debt to EBITDA	not computable	1.82x				
required facts have no common fiscal period end						
Interest coverage	not computable	(4.51x)				
required facts have no common fiscal period end						
Current ratio	0.78x	2.95x		91.6	827	2025-12-31
Growth and financing						
Revenue growth, three-year compound	not computable	10.1%				
four annual observations are required; found 3						
Free cash flow growth, three-year compound	not computable	11.0%				
four consecutive annual FCF observations are required; found 2						
Reinvestment rate	not computable	37.1%				
required facts have no common fiscal period end						
Asset growth, three years	not computable	2.2%				
four consecutive annual observations are required						
Net share issuance, one year	not computable	2.5%				
prior share count is 32 days earlier						

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 0.4 months
Thin data	2 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor
Fortress balance sheet	cash minus debt is 5,970,878 USD; Altman Z is not used

What the price implies

at the 2026-11-11 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(17.6%)	(1.9%)	38
Distance from 52-week high	(51.7%)	(27.8%)	28
EBIT to enterprise value	(0.02%)	(1.6%)	55
Free cash flow yield	(28.6%)	(1.0%)	20
Book value to price	0.19	0.27	40
Sales to price	0.00	0.29	0
Composite equity issuance, five years	785.7%	20.8%	99
Relative strength against the sector, log excess return	(0.36)	(0.19)	38

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$995,977
Operating cash flow, four quarters	-$29.7M
Months of runway	0.4
Days since last periodic filing	90 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	$517,144

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$30.1M	2025-12-31	2026-03-31	10-K	26-134950
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$27.6M	2025-12-31	2026-03-31	10-K	26-134950
3	assets	us-gaap:Assets	$27.4M	2025-12-31	2026-03-31	10-K	26-134950
4	assets	us-gaap:Assets	$20.0M	2024-12-31	2026-03-31	10-K	26-134950
5	current assets	us-gaap:AssetsCurrent	$4.6M	2025-12-31	2026-03-31	10-K	26-134950
6	current liabilities	us-gaap:LiabilitiesCurrent	$5.9M	2025-12-31	2026-03-31	10-K	26-134950
7	revenue	us-gaap:Revenues	$0	2025-12-31	2026-03-31	10-K	26-134950
8	revenue	us-gaap:Revenues	$0	2024-12-31	2026-03-31	10-K	26-134950
9	revenue	us-gaap:Revenues	$0	2012-06-30	2012-12-20	10-K/A	12-001331
10	assets	us-gaap:Assets	$6.2M	2024-06-30	2024-10-07	10-K	24-113321
11	assets	us-gaap:Assets	$4.0M	2023-06-30	2024-10-07	10-K	24-113321
12	shares outstanding	dei:EntityCommonStockSharesOutstanding	63,682,528	2026-04-24	2026-04-30	10-K/A	26-197486
13	shares outstanding	dei:EntityCommonStockSharesOutstanding	63,578,528	2026-03-23	2026-03-31	10-K	26-134950

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.